$90.27
-2.41 (-2.60%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
—
1Y
+490.39%
YTD
+195.19%
Open$92.83
Previous Close$92.68
Day High$93.35
Day Low$89.85
52W High$110.18
52W Low$14.51
Volume—
Avg Volume1.06M
Market Cap8.17B
P/E Ratio—
EPS$-2.32
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$33.24
Above
SMA 200
$22.06
Above
RSI (14)
64.7
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
23 analysts
Price Target
-12.6% upside
Current
$90.27
$90.27
Target
$78.92
$78.92
$58.92
$78.92 avg
$128.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 469.29M | 433.92M | 481.69M |
| Net Income | -23,759,261 | -24,167,490 | -23,392,315 |
| Profit Margin | -5.1% | -5.6% | -4.9% |
| EBITDA | -33,340,073 | -28,197,061 | -36,465,134 |
| Free Cash Flow | -26,670,161 | -19,444,681 | -29,871,207 |
| Rev Growth | +18.1% | +19.4% | +22.5% |
| Debt/Equity | 0.73 | 0.87 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.73 | +0.29% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $392.34 | +1.73% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.59 | +0.99% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $511.29 | +0.58% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $794.14 | +1.18% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.64 | +2.12% | 40.0 | 32.33B |